Outcomes4Me
Outcomes4Me operates an AI-driven platform for cancer patients, providing personalized treatment guidance, clinical trial matching, genomic insights, and symptom tracking. It monetizes through B2B partnerships with pharmaceutical companies and health systems, serving over 400,000 patients globally.
- Company typePrivate
- Founded2017
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingSoftware
What Outcomes4Me does
Outcomes4Me Inc. is a Boston-based digital health company founded in 2017 that operates an AI-driven direct-to-patient platform designed to help cancer patients navigate their care from diagnosis through every stage of treatment. The platform integrates NCCN Clinical Practice Guidelines in Oncology with genomic insights, medication and symptom tracking, clinical trial matching, genetic testing access (via Invitae NGS partnership), and peer community support, using AI to translate clinical information into personalized patient-facing guidance. The technology stack includes patented recommendation, knowledge retrieval, predictive analytics, and process automation capabilities, augmented by acquisitions of EHR-integrated patient data (Geno.Me — Epic, Cerner, Meditech), an AI clinical trial matching engine (Realyze Intelligence), and a certified medical device digital therapeutic (MIKA Health).
The company operates a dual-sided business model: the patient-facing mobile and web application is offered free of charge and serves over 400,000 cancer patients across breast, lung, prostate, colorectal, bladder, ovarian and other cancer types. Revenue is generated on the B2B side through enterprise partnerships with pharmaceutical and life sciences companies — Outcomes4Me reports that seven of the top ten global cancer pharmaceutical companies are customers. B2B revenue streams include subscription-based content and precision marketing, clinical trial recruitment (with 5-10x pre-screen efficiency claimed), and real-world data access leveraging proprietary multimodal patient-level datasets enriched at the drug level. The company has also established research and clinical collaborations with academic cancer centers including Johns Hopkins, Massachusetts General Hospital, Vanderbilt, and UPMC Hillman Cancer Center, and counts Labcorp, NBCUniversal, Pfizer, Foundation Medicine, and CURE among its enterprise partners.
Since commercial launch in 2022, Outcomes4Me has executed a $12M Series A (May 2021), a $21M funding round (May 2025) led by London-based Salica Investments with Labcorp Venture Fund participation, and three acquisitions: MIKA Health (June 2025), Geno.Me (May 2026), and Realyze Intelligence (May 2026). The company is venture-backed with $38M in total capital raised, operates with 11-50 employees, and is led by founder and CEO Maya R. Said, Sc.D., formerly of Novartis.
Outcomes4Me firmographics
Firmographics- Name
- Outcomes4Me
- Legal name
- Outcomes4Me Inc.
- Website
- https://outcomes4me.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Outcomes4Me operates an AI-driven platform for cancer patients, providing personalized treatment guidance, clinical trial matching, genomic insights, and symptom tracking. It monetizes through B2B partnerships with pharmaceutical companies and health systems, serving over 400,000 patients globally.
- Ownership category
- akta.pro rank
Outcomes4Me industry classification
Industry- Product category
- Digital Health - Oncology Patient Empowerment Platform
- NAICS
- Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (62151)
- SIC
- Services-Health Services (8000), Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370)
- akta.pro primary industry
- Oncology Pathways & Precision Medicine Decision Support (HLACAGAH)
- akta.pro secondary industries
- Oncology Remote Symptom Monitoring & Care Navigation (HLALAFAD), Clinical Trial Patient Recruitment & Retention (HLAGACAD), Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials) (HLAAANAI)
Keywords
Where Outcomes4Me is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Outcomes4Me business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Others
Revenue model
- Life Sciences Partnerships: Revenue from pharmaceutical and life sciences companies who partner with Outcomes4Me for patient engagement, content marketing, clinical trial recruitment, and real-world data access. Seven out of the top 10 global cancer pharmaceutical companies are customers.
- Content & Precision Marketing: Lead generation and content integration services for pharmaceutical partners, including awareness campaigns, conversion through custom events, and patient education content that seamlessly integrates real-time information into patient interactions.
- Clinical Trial Recruitment: Pre-screening and recruitment services for clinical trials, providing qualified pre-screened patients with complete medical records and eligibility packets to pharmaceutical and research partners.
- Real-world Data: Access to regulatory-grade outcomes data and real-world evidence capabilities for pharmaceutical and research partners, leveraging proprietary patient-level datasets.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Others | Free patient app |
| Subscription | Annual | Life Sciences Enterprise |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels8 records
Outcomes4Me product offering
Product offeringCore offering
Outcomes4Me operates an AI-driven direct-to-patient platform that empowers cancer patients with personalized treatment guidance, integrating NCCN Clinical Practice Guidelines, genomic insights, clinical trial matching, symptom/medication tracking, and peer community support. The company also generates B2B revenue by partnering with pharmaceutical companies on content marketing, clinical trial recruitment, and real-world data access, with seven of the top 10 global cancer pharmaceutical companies as customers.
Product overview
Outcomes4Me is a single, unified AI-driven direct-to-patient platform for cancer care empowerment, combining core platform capabilities with acquired technologies. The core Outcomes4Me Platform integrates clinical guidelines, genomics, clinical trial matching, and symptom tracking. Acquired brands include Geno.Me (EHR-integrated patient data access), Realyze Intelligence (AI-powered trial matching), and MIKA Health (certified digital therapeutics app). Sub-products include genetic testing partnerships with Invitae and Foundation Medicine, dedicated clinical trial matching tools, and patient peer communities. The platform supports over 400,000 cancer patients across multiple cancer types including breast, prostate, lung, colorectal, bladder, and others.
Differentiator
Problem solved
Functional benefit
Products and services
- Outcomes4Me Platform AI-driven direct-to-patient cancer care empowerment platform that integrates NCCN Clinical Practice Guidelines in Oncology, genomic insights, symptom and medication tracking, clinical trial matching, and peer community support to give cancer patients personalized, evidence-based guidance from diagnosis through every stage of care. Free to patients; supports over 400,000 cancer patients across multiple cancer types.
- Clinical Trial Matching AI-driven clinical trial matching service that connects cancer patients with relevant research opportunities based on diagnosis, biomarkers, and treatment history. Enables 5-10X pre-screen efficiency for clinical trial recruitment offered to pharmaceutical partners.
- Genetic Testing Partnership Services Partnership-driven genetic testing service providing clinical-grade, next-generation sequencing-based testing analyzing more than 80 genes for cancer patients and family members, plus research collaborations on genomic testing awareness with Foundation Medicine.
- Patient Communities Peer support communities connecting patients with similar cancer types, treatment journeys, biomarkers, and lived experiences, including 100+ cancer-type-specific communities with over 700,000 total members.
- Realyze Intelligence AI-powered clinical trial matching platform that extracts oncology data from medical records and automatically identifies clinical trial matches for patients; originally developed at UPMC.
- Geno.Me Patient-controlled health data access platform with integrations to Epic, Cerner, and Meditech electronic health record systems, enabling patients to aggregate and share medical records through Outcomes4Me.
- MIKA Health Certified medical device app clinically proven to help cancer patients cope with their condition through digital therapeutics and personalized recommendations; acquired from Berlin-based Fosanis GmbH.
Quantifiable outcome
- Highest quality application among over 3,000 applications for adults with cancer worldwide (peer-reviewed study in Current Oncology)
- +3 more outcomes
Companies that use Outcomes4Me
Customer profileNamed customers10 records
Segments4 records
Ideal customer profiles3 records
Outcomes4Me technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration5 records
AI capability7 records
Feature6 records
Outcomes4Me partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered flagship, core and strategic.
- UPMC Hillman Cancer CenterflagshipStrategic partnership with UPMC Hillman Cancer Center including appointment of CIO Scot Stevens as Strategic Advisor. Realyze Intelligence technology was initially developed at UPMC.
- InvitaecorePartnership with Invitae providing direct access to genetic testing for cancer patients. Invitae provides clinical-grade next-generation sequencing (NGS) genetic testing analyzing more than 80 genes for cancer patients and family members.
- Foundation Medicine Inc.strategicResearch partnership studying genomic testing awareness and utilization in breast cancer patients. Outcomes4Me collaborated with Foundation Medicine on a study of over 200 breast cancer patients demonstrating discrepancy between willingness to get genomic testing and extent to which it is being offered.
- Johns Hopkins UniversityflagshipWorld-class collaboration with Johns Hopkins University as part of the oncology care provider network supporting patient care and improving patient outcomes.
- Massachusetts General HospitalflagshipWorld-class collaboration with MGH as part of the oncology care provider network supporting patient care and improving patient outcomes.
- VanderbiltflagshipWorld-class collaboration with Vanderbilt as part of the oncology care provider network supporting patient care and improving patient outcomes.
- NCCNflagshipPartnership with National Comprehensive Cancer Network (NCCN) enabling integration with NCCN Clinical Practice Guidelines in Oncology, the first digital platform to do so.
- Wolters KluwerstrategicCollaboration with Wolters Kluwer for evidence-based clinical information supporting the oncology care provider network.
- CUREstrategicPartnership with CURE for the ASCO 2025 Breast Cancer Briefing Room, providing exclusive coverage of ASCO abstracts, sessions and key data specific to breast cancer.
- PfizerstrategicFounder and CEO Maya Said featured on Pfizer's Science Will Win podcast discussing AI in cancer care and the pace of science.
- NBCUniversalstrategicCancer care partnership with NBCUniversal as part of broader consumer engagement initiatives.
- MIKA HealthcoreAcquired from Fosanis GmbH (Germany) in June 2025. MIKA Health is a certified medical device clinically proven to help cancer patients cope with their disease, expanding Outcomes4Me's European presence.
Scale indicators11 records
Recent moves6 records
Expansion highlights6 records
Outcomes4Me competitors and assessment
Company assessmentDirect peers
- Massive Bio: AI-driven clinical trial matching and patient recruitment platform for oncology, closely comparable to Outcomes4Me's trial matching and pharma services offering.
- Carevive: Oncology patient-reported outcomes, symptom management, and care planning platform serving both providers and pharma, comparable to Outcomes4Me's symptom tracking and pharma RWD business.
- Navigating Cancer: Patient engagement platform for oncology practices that combines symptom tracking, patient education, and clinical trial matching, directly comparable to Outcomes4Me's direct-to-patient platform.
Broad incumbents
- Tempus: Precision medicine and AI platform combining genomics, clinical data, and trial matching for oncology. Larger and broader in scope than Outcomes4Me but competes in adjacent precision oncology decision support.
- Flatiron Health: Oncology EHR and real-world data provider for community oncology practices and pharma research, acquired by Roche. Comparable in real-world data and oncology clinical trial enablement, with much broader scale.
- Epic Systems (MyChart): Dominant EHR vendor whose MyChart patient portal is integrated via Geno.Me, and which could either partner with or compete against Outcomes4Me in cancer patient digital engagement.
Emerging players
- CancerIQ: Precision oncology platform focused on cancer risk assessment, genetic testing, and clinical decision support for providers, partially overlapping with Outcomes4Me's genomic integration and decision support capabilities.
- Jasper Health: Digital cancer care platform providing personalized guidance, care navigation, and peer support for cancer patients, closely comparable to Outcomes4Me's patient-facing consumer model.
- VivorCare: Specialized digital care platform for oncology patients focused on financial assistance and care navigation, with partial overlap to Outcomes4Me's patient empowerment value proposition.
Others
- Foundation Medicine: Genomic profiling and molecular information partner of Outcomes4Me; comparable in oncology precision and clinical research support, and a current collaboration partner.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Outcomes4Me social profiles
Digital presenceOutcomes4Me financial estimates
Financial estimateRevenue estimate
Valuation estimate
Outcomes4Me leadership team
Management profileNumber of profiles
Profiles10 records
Outcomes4Me subsidiaries and ownership
Company hierarchySubsidiaries3 records
Outcomes4Me funding detail
Funding detailFunding overview
Funding rounds3 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Outcomes4Me M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Outcomes4Me
What does Outcomes4Me do?
Outcomes4Me operates an AI-driven direct-to-patient platform that empowers cancer patients with personalized treatment guidance, integrating NCCN Clinical Practice Guidelines, genomic insights, clinical trial matching, symptom/medication tracking, and peer community support. The company also generates B2B revenue by partnering with pharmaceutical companies on content marketing, clinical trial recruitment, and real-world data access, with seven of the top 10 global cancer pharmaceutical companies as customers.
Is Outcomes4Me a public or private company?
Outcomes4Me is a private company. It is classified as venture growth investor backed and is currently operating.
When was Outcomes4Me founded?
Outcomes4Me was founded in 2017. It employs 11 to 50 people.
Where is Outcomes4Me based?
Outcomes4Me is headquartered in Boston, United States, in the North America region.
How does Outcomes4Me make money?
Four revenue lines are on record. Life Sciences Partnerships are the primary driver. The others are content & Precision Marketing, clinical Trial Recruitment and real-world Data.
Who are Outcomes4Me's main competitors?
Direct peers on record are Massive Bio, Carevive and Navigating Cancer. Broad incumbents are Tempus, Flatiron Health and Epic Systems (MyChart). Emerging players are CancerIQ, Jasper Health and VivorCare. Foundation Medicine is listed as an others.
Does Outcomes4Me have an API?
No public API is recorded for Outcomes4Me.
What industry is Outcomes4Me in?
Outcomes4Me's product category is Digital Health - Oncology Patient Empowerment Platform. Its primary akta.pro industry code is HLACAGAH, Oncology Pathways & Precision Medicine Decision Support, with a secondary code of HLALAFAD, Oncology Remote Symptom Monitoring & Care Navigation. Its NAICS code is 5417 and its SIC code is 8000.